Aileron Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview

Rein Therapeutics

02/11/2024 04:03

* Aileron Therapeutics Inc  ALRN.OQ   ALRN.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 4 (estimated) for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Aileron Therapeutics Inc
is
for a loss of 41 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aileron
Therapeutics Inc is 13.00​, above​ its last closing price
of $4.00. ​​​

This summary was machine generated November 2 at 04:03 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)